Literature DB >> 16951245

Liver intestine-cadherin (CDH17) haplotype is associated with increased risk of hepatocellular carcinoma.

Xiao Qi Wang1, John M Luk, Mercè Garcia-Barcelo, Xiaoping Miao, Pauline P Leung, David W Ho, Siu Tim Cheung, Brian Y Lam, Cindy K Cheung, Ashley S Wong, Silvana S Lau, Man Ting So, Wan Ching Yu, Qi Cai, Karen S Liu, Chee Kin Hui, George K Lau, Ronnie T P Poon, John Wong, Sheung Tat Fan.   

Abstract

PURPOSE: Hepatocellular carcinoma (HCC), the most common form of liver cancer, is a leading cause of cancer death worldwide. We previously showed that aberrant mRNA splicing of the liver intestine-cadherin gene CDH17 in liver tissues was triggered by the specific constellation of two CDH17 single nucleotide polymorphisms (651T and IVS6+35G). CDH17 aberrant splicing was highly associated with tumor dissemination and shorter survival of HCC patients. Consequently, it is highly relevant to assess whether the presence of these single nucleotide polymorphisms in the general population represents a risk to the development of HCC. EXPERIMENTAL
DESIGN: We conducted a case-control study including 164 HCC and 99 cirrhosis patients and 293 healthy controls. Genotyping was done by PCR and direct sequencing. Odds ratio (OR) and chi2 analysis were used to analyze genotypes and haplotypes.
RESULTS: Genotypes 651TT [OR, 2.62; 95% confidence interval (95% CI), 1.34-5.03] and IVS6+35 GG (OR, 1.95; 95% CI, 1.04-3.62) were highly associated with HCC disease. The 651T (C>T) and IVS6+35G (A>G) alleles were also overrepresented in HCC patients and, in particular, the T-G haplotype was the most prevalent in HCC patients when compared with healthy controls (OR, 1.57; 95% CI, 1.167-2.109; P=0.004), which was in agreement with the aberrant splicing observed in tumor tissues. There was no significant difference in genotype and allele frequencies between cirrhosis patients and controls.
CONCLUSION: The functional T-G haplotype of CDH17 (651 C>T and IVS6+35A>G) is a genetic susceptibility factor for the development of HCC in a Chinese population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16951245     DOI: 10.1158/1078-0432.CCR-06-0558

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  12 in total

Review 1.  Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences.

Authors:  Carmen Berasain; Saioa Goñi; Josefa Castillo; María Ujue Latasa; Jesús Prieto; Matías A Avila
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

2.  Blockade of proliferation and migration of gastric cancer via targeting CDH17 with an artificial microRNA.

Authors:  Jin Zhang; Qi-Sheng Liu; Wei-Guo Dong
Journal:  Med Oncol       Date:  2011-06       Impact factor: 3.064

3.  Cadherin-17 induces tumorigenesis and lymphatic metastasis in gastric cancer through activation of NFκB signaling pathway.

Authors:  Jin Wang; Wei-Ming Kang; Jian-Chun Yu; Yu-Qin Liu; Qing-Bin Meng; Zhan-Jiang Cao
Journal:  Cancer Biol Ther       Date:  2013-01-08       Impact factor: 4.742

4.  Dickkopfs and Wnt/β-catenin signalling in liver cancer.

Authors:  Sarwat Fatima; Nikki P Lee; John M Luk
Journal:  World J Clin Oncol       Date:  2011-08-10

5.  Single nucleotide polymorphisms in the CDH17 gene of colorectal carcinoma.

Authors:  Ren-Yin Chen; Juan-Juan Cao; Juan Chen; Jian-Ping Yang; Xiao-Bo Liu; Guo-Qiang Zhao; Yu-Feng Zhang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

Review 6.  Involvement of liver-intestine cadherin in cancer progression.

Authors:  Masaaki Takamura; Satoshi Yamagiwa; Yasunobu Matsuda; Takafumi Ichida; Yutaka Aoyagi
Journal:  Med Mol Morphol       Date:  2013-01-10       Impact factor: 2.309

7.  Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach.

Authors:  Jie Gao; Jun Zhou; Xiao-Pei He; Yun-Fei Zhang; Na Gao; Xin Tian; Yan Fang; Qiang Wen; Lin-Jing Jia; Han Jin; Hai-Ling Qiao
Journal:  Oncotarget       Date:  2016-05-10

8.  Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma.

Authors:  Ling Xiao Liu; Nikki P Lee; Vivian W Chan; Wen Xue; Lars Zender; Chunsheng Zhang; Mao Mao; Hongyue Dai; Xiao Lin Wang; Michelle Z Xu; Terence K Lee; Irene O Ng; Yangchao Chen; Hsiang-fu Kung; Scott W Lowe; Ronnie T P Poon; Jian Hua Wang; John M Luk
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

9.  Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/β-catenin signaling.

Authors:  Hai-bo Qiu; Li-yi Zhang; Chao Ren; Zhao-lei Zeng; Wen-jing Wu; Hui-yan Luo; Zhi-wei Zhou; Rui-hua Xu
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

10.  Anti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma.

Authors:  Yonggang Wang; Felix H Shek; Kwong F Wong; Ling Xiao Liu; Xiao Qian Zhang; Yi Yuan; Ester Khin; Mei-Yu Hu; Jian Hua Wang; Ronnie T P Poon; Wanjin Hong; Nikki P Lee; John M Luk
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.